函王
Lv11
80 积分
2023-12-13 加入
-
Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial
2小时前
求助中
-
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
27天前
已完结
-
Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial
1个月前
已完结
-
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
1个月前
已关闭
-
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
1个月前
已完结
-
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
1个月前
已完结
-
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
2个月前
已完结
-
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
2个月前
已完结
-
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
2个月前
已完结
-
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
2个月前
已完结